May 16, 2019
Entrectinib shrank tumours ORR in all children and adolescents: Roche study
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.